Life Science Intelligence

Medtech continuously develops some of the best leaders in any industry. The combination of putting patients first by saving and extending lives, while leading world class teams who produce some of the most innovative technology platforms requires agile, thoughtful and courageous leadership. For more information watch this video https://www.lifesciencemarketresearch.com/videos/leadership-in-the-workplace-panel-w-leslie-trigg-nadine-hachach-haram-amy-raimundo

Bryan, Elliot, and Berk are CEO's who are leading organizations with disruptive platforms in medtech. These companies are bringing value beyond the acute delivery of care. Access, value, and outcomes are an umbrella of solutions beyond the procedure itself. For more information watch this video https://www.lifesciencemarketresearch.com/videos/emerging-trends-panel-w-bryan-lord-elliot-street-md-berk-tas

Under the leadership of Co-Founder and CEO Evan Luxon and CBO Randy Preston, Centese is rewriting the playbook for recovery following heart and lung surgery. With more than 15,000 patients treated to date, Centese’s intelligent surgical recovery platform, Thoraguard, is accelerating recovery times, reducing complications, and reshaping the post-operative experience for cardiothoracic patients. From Incubator  to Impact Centese  originated inside San Francisco-based medical device incubator  TheraNova , where  Evan Luxon  worked as Partner in new product development. While researching the clinical benefit of an automated urine output monitoring device, a chance conversation with cardiac surgeons sparked a new idea. "They asked us if we could do something similar for chest drains," Luxon recalled. "Those devices were even harder to manage, played an integral role in highly complex procedures, and hadn't seen innovation in decades. That was the spark." TheraNova fo...

Under the direction of Founder and CTO Tarek Makansi, StimAire is developing a surgery-free neuromodulation platform to treat obstructive sleep apnea (OSA) without surgery, CPAP machines, or daily maintenance. Origin Story Tarek Makansi is no stranger to solving big problems with elegant engineering. With a BS from Cornell and a PhD from UC Berkeley in electrical engineering, he began his career in data storage at IBM, where he rose to executive leadership and eventually served as CTO for IBM’s Venture Capital Group. “I was scouting the world for startup companies for IBM to acquire,” he said. “Then I left after 20 years and started Tempronics, which was sold to a Fortune 500 company.” In 2017, after observing the bulky nature of neuromodulation systems, which typically involve large pacemaker-like implants wired to peripheral nerves, Makansi saw an opportunity to rethink the model entirely. “I noticed that for neuromodulation, people were using a large implant in the chest or the back...

Under the direction of Founder and CEO Nader Sadrzadeh, DeepSight Technology is redefining ultrasound for the interventional era. Based in Santa Clara at the heart of Silicon Valley with additional operations in Missouri, the company has developed proprietary sensor and imaging platforms that deliver crystal-clear, real-time visualization directly from inside the body. With its NeedleVue™ technology, DeepSight is positioning ultrasound not just as a diagnostic aid, but as a central guidance system for minimally invasive therapies. Origin Story DeepSight’s beginnings trace back to academic innovation. “DeepSight was founded on the strength of a remarkable technology developed by my co-founder, Dr. Lan Yang, at Washington University in St. Louis,” Sadrzadeh explained. He was introduced to Yang through Gaurav Garg at Wing Venture Capital, who ultimately became the company’s seed investor, board member, and a guiding force. “Together with Anand Chandrasheker, we saw that ultrasound was at ...

  LSI Europe   ’25 has wrapped, marking the fourth   Emerging Medtech Summit   in Europe and the 11th globally. Nearly 1,000   industry leaders   convened in London, generating thousands of meetings and countless opportunities. In the days since, conversations about deals, partnerships, and future collaborations have already started to surface. This summit is about more than presentations; it is where investors, strategics, and entrepreneurs come together to shape the future of healthcare. With more than 200 startups presenting their technologies, commercial milestones, and fundraising goals, the event spotlighted the breadth of innovation happening across the industry. Emerging Medtech Companies to Watch Among those presenting, five emerging medtech companies captured particular attention for their market opportunities, recent progress, and potential to disrupt entrenched approaches. Below, we look at the numbers and context behind each one. This blog is o...

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce strategic partnerships, achieve clinical milestones, and much more on the road to  LSI USA ‘26   in Dana Point (March 16–20). Adagio Medical Announced that it entered into a securities purchase agreement worth up to $50M in proceeds, with the agreement expected to result in ~$19M in upfront proceeds. The company plans to use the funds for working capital and general corporate purposes, including the advancement of its clinical and product development activities. Avisi Technologies Announced that the FDA has approved an IDE submission for its VisiPlate Ⓡ  for glaucoma treatment. The SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with one-year follow-up that will evaluate the safety and effectiveness of its VisiPlate aqueous shunt. Berlin Heals Completed enrollment in the first-in-human Phase I CMIC-III study e...

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, achieve clinical and regulatory milestones, and much more on the road to  LSI USA ‘26   in Dana Point (March 16–20). Adagio Medical Completed enrollment of the FULCRUM-VT pivotal FDA IDE study evaluating its ventricular tachycardia-specific ablation technology, with 208 patients across 20 centers. Adagio’s vCLAS™ Cryoablation System, which uses proprietary ultra-low temperature cryoablation (ULTC) technology, is being evaluated to support FDA pre-market approval for the treatment of monomorphic ventricular tachycardia. AiM Medical Robotics Raised $8.1M in Series A funding to advance its MRI-compatible surgical robotics platform for neurosurgery applications. The company will use the proceeds to fund its first-in-human clinical study, expand strategic partnerships, and accelerate product development and regulatory progress. CorWave Reported encour...